Cheryl Pegus
Cheryl Pegus's purchase track record
Cheryl Pegus has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2026 | BSX | $100K | -8.2% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
CON reaches 52‑week high amid health sector activity. Concentra Group Holdings rose to a 52‑week high of $36.83. The move comes as other health‑care companies reported developments, such as Teladoc adding AI‑driven care tools and Encompass Health opening a new rehabilitation hospital in Maine. The stock’s momentum is reflected in an RSI above 60 and recent support around $22.25.
Transaction History
| BSX | ▲ Buy | Open Market | 1,770 | $100K | 5/20/2026 | View on chart |
| CON | ▲ Buy | Grant | 7,748 | $0 | 11/4/2025 | View on chart |
| CON | ▲ Buy | Grant | 6,496 | $0 | 11/26/2024 | View on chart |
| CON | ▲ Buy | Grant | 6,496 | $0 | 11/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.